1
Stéphane De Lombaert
DE LOMBAERT Stéphane, LIU Weimin, LO Ho Yin, NEMOTO Peter Allen: INHIBITEURS BENZIMIDAZOLE DE PRODUCTION DE LEUCOTRIÈNES, BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION. BOEHRINGER INGELHEIM INTERNATIONAL, DE LOMBAERT Stéphane, LIU Weimin, LO Ho Yin, NEMOTO Peter Allen, MORRIS Michael P, May 10, 2012: WO/2012/061169 (1 worldwide citation)

The present invention relates to compounds of formula (IA), (IB) and (IC) and pharmaceutically acceptable salts thereof, wherein R1-R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of var ...


2
Kevin Rodzinak
Philip E Sanderson, Mark E Layton, Kevin J Rodzinak: Inhibitors of akt activity. December 29, 2011: US20110319443-A1

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


3
Tarran Jones
David M Hilbert, Tarran Jones, David G Williams: Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. Medimmune, July 28, 2011: US20110182887-A1

The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and four human or humanized framework r ...


4
Kevin Rodzinak
Hidetomo Furuyama, Yasuhiro Goto, Nobuhiko Kawanishi, Mark E Layton, Takashi Mita, Akira Naya, Yoshio Ogino, Yu Onozaki, Kevin J Rodzinak, Toshihiro Sakamoto, Philip E Sanderson, Jiabing Wang: Inhibitors of akt activity. April 21, 2011: US20110092511-A1

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods ...


5
Kevin Rodzinak
Donna J Armstrong, Essa H Hu, Michael J Kelly III, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Michael A Rossi, Philip E Sanderson, Jiabing Wang: Inhibitors of akt activtiy. Merck, September 2, 2010: US20100222321-A1

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


6
Toufike Kanouni
Qing Dong, Xianchang Gong, Stephen W Kaldor, Toufike Kanouni, Nicholas Scorah, Michael B Wallace, Feng Zhou: MAPK/ERK KINASE INHIBITORS. TAKEDA PHARMACEUTICAL COMPANY, TAKEDA SAN DIEGO, May 27, 2010: US20100130518-A1

Compounds of the following formula are provided for use with MEK (I): wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of usin ...


7

8
Toufike Kanouni
Qing Dong, Xianchang Gong, Stephen W Kaldor, Toufike Kanouni, Nicholas Scorah, Michael B Wallace, Feng Zhou: Mapk/erk kinase inhibitors. Takeda San Diego, October 16, 2008: US20080255160-A1

Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using sa ...


9
Tarran Jones
Goldstein Neil I, Giorgio Nicholas A, Jones Steven Tarran, Saldanha Jose William: Antibody and antibody fragments for inhibiting the growth of tumors. Imclone Systems, April 1, 1998: EP0831880-A1

Chimerized and humanized versions of anti EGF receptor antibody 225 and fragments thereof for treatment of tumors.


10
Lee Funk
Jingrong Jean Cui, Lee Andrew Funk, Lei Jia, Pei Pei Kung, Jerry Jialun Meng, Mitchell David Nambu, Mason Alan Pairish, Hong Shen, Michelle Tran Dube: Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors. Agouron Pharmaceuticals, October 18, 2012: US20120263706-A1

Enantiomerically pure compound of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.